Phase II study of satraplatin and prednisone in patients with metastatic castration-resistant prostate cancer: A pharmacogenetic assessment of outcome and toxicity
Authors
William D. Figg, National Institutes of Health (NIH), Bethesda, MD
Cindy H. Chau, National Institutes of Health (NIH), Bethesda, MD
Ravi A. Madan, National Institutes of Health (NIH), Bethesda, MD
James L. Gulley, National Institutes of Health (NIH), Bethesda, MD
Rui Gao, National Institutes of Health (NIH), Bethesda, MD
Tristan M. Sissung, National Institutes of Health (NIH), Bethesda, MD
Shawn Spencer, National Cancer Institute at Frederick, Bethesda, MD
Melony Beatson, National Institutes of Health (NIH), Bethesda, MD
Jeanny B. Aragon-Ching, George Washington UniversityFollow
Seth M. Steinberg, National Institutes of Health (NIH), Bethesda, MDFollow
William L. Dahut, National Institutes of Health (NIH), Bethesda, MD
Document Type
Journal Article
Journal
Clinical Genitourinary Cancer
APA Citation
[Epub ahead of print]
